Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D

Joel Zonszein, Manuel Lombardero, Faramarz Ismail-Beigi, Pasquale Palumbo, Suzy Foucher, Yolanda Groenewoud, Gary Cushing, Bernardo Wajchenberg, Saul Genuth

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Glycemic management is central in prevention of small vessel and cardiovascular complications in type 2 diabetes. With the plethora of newer medications and recommendations for a patient centered approach, more information is necessary to match the proper drug to each patient. We showed that BARI 2D, a five-year trial designed to compare two different glycemic treatment strategies, was suitable for assessing different responses according to different phenotypic characteristics. Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Triglyceride and high density lipoprotein ratio (TG/HDL-cholesterol ratio) was found to be a readily available and practical biomarker that helps to identify the insulin resistant patient. These results support the concept that not all medications for glycemic control work the same in all patients. Thus, tailored therapy can be done using phenotypic characteristics rather than a "one-size-fits-all approach."

Original languageEnglish (US)
Article number129891
JournalJournal of Diabetes Research
Volume2015
DOIs
StatePublished - 2015

Fingerprint

HDL Lipoproteins
Type 2 Diabetes Mellitus
Triglycerides
Insulin
Pharmaceutical Preparations
Thiazolidinediones
Metformin
HDL Cholesterol
Therapeutics
Biomarkers

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes : A Post Hoc Analysis of the BARI 2D. / Zonszein, Joel; Lombardero, Manuel; Ismail-Beigi, Faramarz; Palumbo, Pasquale; Foucher, Suzy; Groenewoud, Yolanda; Cushing, Gary; Wajchenberg, Bernardo; Genuth, Saul.

In: Journal of Diabetes Research, Vol. 2015, 129891, 2015.

Research output: Contribution to journalArticle

Zonszein, Joel ; Lombardero, Manuel ; Ismail-Beigi, Faramarz ; Palumbo, Pasquale ; Foucher, Suzy ; Groenewoud, Yolanda ; Cushing, Gary ; Wajchenberg, Bernardo ; Genuth, Saul. / Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes : A Post Hoc Analysis of the BARI 2D. In: Journal of Diabetes Research. 2015 ; Vol. 2015.
@article{81ce5b77d4434feea932ed69cf92bf4e,
title = "Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D",
abstract = "Glycemic management is central in prevention of small vessel and cardiovascular complications in type 2 diabetes. With the plethora of newer medications and recommendations for a patient centered approach, more information is necessary to match the proper drug to each patient. We showed that BARI 2D, a five-year trial designed to compare two different glycemic treatment strategies, was suitable for assessing different responses according to different phenotypic characteristics. Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Triglyceride and high density lipoprotein ratio (TG/HDL-cholesterol ratio) was found to be a readily available and practical biomarker that helps to identify the insulin resistant patient. These results support the concept that not all medications for glycemic control work the same in all patients. Thus, tailored therapy can be done using phenotypic characteristics rather than a {"}one-size-fits-all approach.{"}",
author = "Joel Zonszein and Manuel Lombardero and Faramarz Ismail-Beigi and Pasquale Palumbo and Suzy Foucher and Yolanda Groenewoud and Gary Cushing and Bernardo Wajchenberg and Saul Genuth",
year = "2015",
doi = "10.1155/2015/129891",
language = "English (US)",
volume = "2015",
journal = "Journal of Diabetes Research",
issn = "2314-6745",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes

T2 - A Post Hoc Analysis of the BARI 2D

AU - Zonszein, Joel

AU - Lombardero, Manuel

AU - Ismail-Beigi, Faramarz

AU - Palumbo, Pasquale

AU - Foucher, Suzy

AU - Groenewoud, Yolanda

AU - Cushing, Gary

AU - Wajchenberg, Bernardo

AU - Genuth, Saul

PY - 2015

Y1 - 2015

N2 - Glycemic management is central in prevention of small vessel and cardiovascular complications in type 2 diabetes. With the plethora of newer medications and recommendations for a patient centered approach, more information is necessary to match the proper drug to each patient. We showed that BARI 2D, a five-year trial designed to compare two different glycemic treatment strategies, was suitable for assessing different responses according to different phenotypic characteristics. Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Triglyceride and high density lipoprotein ratio (TG/HDL-cholesterol ratio) was found to be a readily available and practical biomarker that helps to identify the insulin resistant patient. These results support the concept that not all medications for glycemic control work the same in all patients. Thus, tailored therapy can be done using phenotypic characteristics rather than a "one-size-fits-all approach."

AB - Glycemic management is central in prevention of small vessel and cardiovascular complications in type 2 diabetes. With the plethora of newer medications and recommendations for a patient centered approach, more information is necessary to match the proper drug to each patient. We showed that BARI 2D, a five-year trial designed to compare two different glycemic treatment strategies, was suitable for assessing different responses according to different phenotypic characteristics. Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Triglyceride and high density lipoprotein ratio (TG/HDL-cholesterol ratio) was found to be a readily available and practical biomarker that helps to identify the insulin resistant patient. These results support the concept that not all medications for glycemic control work the same in all patients. Thus, tailored therapy can be done using phenotypic characteristics rather than a "one-size-fits-all approach."

UR - http://www.scopus.com/inward/record.url?scp=84935835454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935835454&partnerID=8YFLogxK

U2 - 10.1155/2015/129891

DO - 10.1155/2015/129891

M3 - Article

C2 - 26106623

AN - SCOPUS:84935835454

VL - 2015

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

SN - 2314-6745

M1 - 129891

ER -